The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 572-579

  Shetti, Madhu B ^a   Merrick, Gregory S ^c   Butler, Wayne M ^c   Galbreath, Robert ^c   Torlone, Ashley ^c   Lief, Jonathan H ^c   Adamovich, Edward ^d   Wallner, Kent E ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

brachytherapy; diabetes mellitus; overall survival; prostate cancer

Indexed keywords

TESTOSTERONE;

AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORGAN SIZE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE; PROSTATE CANCER; RISK ASSESSMENT; SMOKING; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; BRACHYTHERAPY; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PALLADIUM; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84870236263     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31822dfd8a     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: GENERAL Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: u.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
2. Bonovas S, Filiousso K, Tsantes A. Diabetes mellitus and risk of prostate cancer: A meta-analysis. Diabetologia. 2004;47:1071-1078. (Pubitemid 38918167)
3. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056-2062. (Pubitemid 44877026)
4. Rodrigues C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161:147-152. (Pubitemid 40096789)
5. Baradaran N, Ahmadi H, Salem S, et al. The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones. Prostate. 2009;69:1744-1750.
6. Pierce BL, Plymate S, Ostrander EA, et al. Diabetes mellitus and prostate cancer risk. Prostate. 2008;68:1126-1132. (Pubitemid 351875184)
7. Waters KM, Henderson BE, Stram DO, et al. Association of diabetes with prostate cancer risk in multiethnic cohort. Am J Epidemiol. 2009;169:937-945.
8. Coker AL, Sanderson M, Zheng W, et al. Diabetes mellitus and prostate cancer risk among older men: Population-based casecontrol study. Br J Cancer. 2004;90:2171-2175. (Pubitemid 38869725)
9. Loeb S, Helfand BT, Kan D, et al. Does diabetes mellitus modify the association between 17q12 risk variant and prosate cancer aggressiveness? BJU Int. 2009;104:1200-1203.
10. Gong Z, NMeuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15: 1977-1983. (Pubitemid 44664277)
11. Leitzmann MF, Ahn J, Albanes D, et al. Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control. 2008;19: 1267-1276.
12. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79: 1336-1342.
13. Snyder CF, Stein KB, Barone BB, et al. Does pre-existing diabetes affect prostate cancer prognosis? Prostate Cancer Prostatic Dis. 2010;13:58-64.
14. Barone BB, Yeh H, Snyder CF, et al. Long-term all cause mortality in cancer patients with pre-existing diabetes mellitus: A systemic review and meta-analysis. JAMA. 2008;300:2754-2764.
15. Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: rtog 92-02. J Clin Oncol. 2008;26:4333-4339.
16. D'Amico AV, Braccioforte MH, Moran BJ, et al. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77:1329-1337.
17. Van De Poll-Franse LV, Hourterman S, Janssen-Heijnen MLG, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis. Int J Cancer. 2007;120:1986-1992. (Pubitemid 46418378)
18. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-848. (Pubitemid 34017254)
19. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol. 2000;6:78-84. (Pubitemid 30227179)
20. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:e178-e189.
21. Rivard MJ, Butler WM, DeWerd LA, et al. Supplement to the 2004 update of the AAPM Task Group No 43 Report. Med Phys. 2007;34:2187-2205.
22. Beyer D, Nath R, Butler WM, et al. American brachytherapy society recommendations for clinical implementation of NIST- standards for (103) palladium brachytherapy: The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2000;47:273-275. (Pubitemid 30236365)
23. Kuman DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487-1493. (Pubitemid 44425220)
24. Merrick GS, Butler WM, Galbreath RW, et al. Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. BJU Int. 2010;107:226-233.
25. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation. 1979;59:8-13. (Pubitemid 9082394)
26. Charlton J, Latinovic R, Gulliford M. Explaining the decline in early mortality in men and women with type 2 diabetes. Diabetes Care. 2008;31:1761-1766.
27. Jayachandran J, Aronson WJ, Terris MK, et al. Diabetes and outcomes after radical prostatectomy: Are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev. 2010;19:9-17.
28. Abdollah F, Briganti A, Suardi N, et al. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis. 2010; advance online publication.
29. Chan JM, Latini DM, Cowan J, et al. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control. 2005; 16:789-797. (Pubitemid 41160043)